Axonal degeneration is a fundamental pathological process shared across neurodegenerative diseases, yet the specific mechanisms, triggers, and clinical manifestations differ significantly between conditions. This comparison page examines how axonal degeneration manifests in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Unlike neuronal cell body death, axonal degeneration often occurs as an early, independent event—making it a critical therapeutic target for preserving neuronal connectivity and function before irreversible damage occurs.
Axonal degeneration is a fundamental pathological process shared across neurodegenerative diseases, yet the specific mechanisms, triggers, and clinical manifestations differ significantly between conditions. This comparison page examines how axonal degeneration manifests in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Unlike neuronal cell body death, axonal degeneration often occurs as an early, independent event—making it a critical therapeutic target for preserving neuronal connectivity and function before irreversible damage occurs.
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Axonal Abnormality | Distal axonopathy, tau-mediated transport disruption | Dopaminergic axon loss in substantia nigra | Motor neuron axon degeneration | Frontotemporal network axonal dysfunction | Striatal medium spiny neuron axon degeneration |
| Key Trigger | Amyloid-beta, tau hyperphosphorylation | Alpha-synuclein aggregation, mitochondrial dysfunction | TDP-43/SOD1 aggregation, excitotoxicity | TDP-43, progranulin, tau | Mutant huntingtin, transcriptional dysregulation |
| Affected Tracts | Corticocortical, hippocampal connections | Nigrostriatal, autonomic fibers | Corticospinal, peripheral nerves | Frontotemporal connections, U-fibers | Striatocortical, corticostriatal |
| SARM1 Involvement | Moderate (energy failure) | High (PINK1/Parkin pathway) | High (energy crisis) | Moderate | High (metabolic dysfunction) |
| Transport Defect | Kinesin dysfunction, microtubule disruption | Dynein dysfunction, mitochondrial transport | Kinesin/dynein impairment | Variable by subtype | Motor protein dysfunction |
| Myelin Involvement | Secondary demyelination | Secondary demyelination | Primary and secondary | Variable | Secondary |
| Clinical Correlation | Early cognitive decline | Motor symptoms, autonomic dysfunction | Weakness, spasticity | Behavior/language changes | Chorea, cognitive decline |
In Alzheimer's disease, axonal degeneration occurs early and progresses throughout the disease course. Key mechanisms include:
Tau-Mediated Transport Disruption
Pathological tau hyperphosphorylation disrupts microtubule stability, impairing axonal transport of organelles, vesicles, and signaling molecules. Tau accumulation in axons correlates with cognitive decline and precedes neurofibrillary tangle formation in vulnerable brain regions [@trojanowski2002].
Amyloid-Beta Toxicity
Aβ oligomers directly impair axonal transport through:
Therapeutic Implications: Strategies targeting tau pathology, microtubule stabilization, and axonal protection (e.g., SARM1 inhibitors) are actively being investigated [@coleman2023].
Parkinson's disease features prominent axonal degeneration, particularly in dopaminergic neurons:
Dopaminergic Axon Vulnerability
The long, unmyelinated axons of substantia nigra pars compacta neurons are particularly vulnerable due to:
Axonal Spheroids
PD brains show widespread axonal spheroids—beaded, swollen axons indicating transport breakdown. These precede Lewy bodies and neuronal loss.
ALS features aggressive axonal degeneration of motor neurons:
TDP-43 Pathology
TDP-43 aggregates in motor neuron axons disrupt:
FTD shows heterogeneous axonal involvement depending on the subtype:
TDP-43 Pathological Subtypes
Huntington's disease features early axonal pathology in striatal and cortical neurons:
Mutant Huntingtin Effects
mHTT disrupts:
All five diseases share several common axonal degeneration pathways:
The SARM1 pathway is a universal executor of axonal death across neurodegenerative conditions:
Mitochondrial impairment is universal:
All diseases show transport defects:
Calcium homeostasis disruption:
| Target | Approach | Disease Relevance | Status |
|--------|----------|-------------------|--------|
| SARM1 Inhibitors | NAD+ preservation | All diseases | Pre-clinical/Phase 1 |
| Microtubule Stabilizers | Transport restoration | AD, FTD | Clinical trials |
| Mitochondrial Protectants | Energy preservation | PD, ALS, HD | Clinical trials |
| Calcium Channel Blockers | Calpain inhibition | AD, ALS | Pre-clinical |
| Kinesin Modulators | Transport enhancement | AD, PD | Pre-clinical |
| TDP-43 Aggregation Inhibitors | RNA transport | ALS, FTD | Pre-clinical |
| NMNAT2 Enhancers | Axonal NAD+ support | All diseases | Pre-clinical |
| NCT ID | Target | Disease | Phase | Status |
|--------|--------|---------|-------|--------|
| NCT05633490 | SARM1 inhibitor | ALS | Phase 1 | Recruiting |
| NCT05318985 | Sodium phenylbutyrate/taurursodiol | ALS | Phase 3 | Completed |
| NCT04831814 | Edaravone | ALS | Phase 3 | Completed |
| NCT04260360 | CoQ10 | PD | Phase 2 | Completed |
| NCT03710156 | Inosine | PD | Phase 2 | Completed |
| NCT03062418 | Pioglitazone | AD | Phase 2 | Completed |
| NCT01767311 | Lecanemab | AD | Phase 3 | Completed |
| Gene | Function | Disease Association |
|------|----------|---------------------|
| KIF5A | Kinesin heavy chain | ALS, HSP |
| KIF1A | Anterograde transport | Hereditary spastic paraplegia |
| DCTN1 | Dynactin subunit | ALS, PD |
| SPG11 | Spastizin | Hereditary spastic paraplegia |
| SPAST | Spastin | Hereditary spastic paraplegia |
| Gene | Function | Disease Association |
|------|----------|---------------------|
| NMNAT2 | NAD+ synthesis | Axonal maintenance |
| SARM1 | NADase | Axonal degeneration execution |
| WLDs | NMNAT1-UCHL1 fusion | Axonal protection (mouse) |
| ATL3 | Atlastin | Hereditary neuropathy |
| Gene | Disease | Role |
|------|---------|------|
| MAPT | AD, FTD | Tau pathology, transport disruption |
| SNCA | PD | Lewy neurite formation |
| TARDBP | ALS, FTD | RNA transport dysfunction |
| SOD1 | ALS | Mitochondrial dysfunction |
| HTT | HD | Transcriptional dysregulation |
| GRN | FTD | Lysosomal dysfunction |
| Biomarker | Disease | Source | Significance |
|-----------|---------|--------|--------------|
| Neurofilament light (NfL) | ALS, PD, AD | CSF, blood | Axonal damage marker |
| phosphorylated tau (p-tau) | AD | CSF | Axonal tau pathology |
| α-Synuclein PTMs | PD | CSF | Axonal Lewy pathology |
| TDP-43 fragments | ALS, FTD | CSF | Axonal TDP-43 pathology |